Flonoltinib (TFA)

Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity[1].

Product Specifications

CAS Number

[2928093-29-0]

Product Name Alternative

JAK2/FLT3-IN-1 (TFA)

UNSPSC

12352005

Target

Apoptosis; FLT3; JAK

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/flonoltinib-tfa.html

Concentration

10mM

Purity

98.94

Solubility

H2O : 33.33 mg/mL (ultrasonic)

Smiles

OCCN(C1CCN(C2=CC=C(NC3=NC=C(C)C(C4=CN(C(C)C)N=C4)=N3)C=C2F)CC1)C.O=C(O)C(F)(F)F

Molecular Formula

C27H35F4N7O3

Molecular Weight

581.61

References & Citations

[1]Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.